Dailypharm Live Search Close

Hugel receives FDA approval for its botulinum toxin Letybo

By Nho, Byung Chul | translator Kim, Jung-Ju

24.03.04 08:05:04

°¡³ª´Ù¶ó 0
First and only Korean company to enter all 3 global botulinum toxin markets (U.S., China, and Europe)

The U.S. market is expected to nearly double from KRW 3.25 trillion in 2023 to KRW 6.36 trillion in 2031



On the 4th, Hugel, a global total medical aesthetics company, announced that the company has received marketing approval from the U.S. Food and Drug Administration (FDA) on February 29th for 50 units and 100 units of its botulinum toxin Letybo (Korean brand name: Botulax).

The FDA approval of Letybo represents a strong affirmation of Hugel's product quality and credibility, as it has met the rigorous standards of one of the world's leading regulatory authorities. It also further underscores the company¡¯s global leadership position.

With the approval, Hugel has become the first and only Korean company and one of the top 3 players globally that have obtained market approvals in th

Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)